Evercore ISI analyst Gavin Clark-Gartner has maintained their bullish stance on MIRM stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Gavin Clark-Gartner has given his Buy rating due to a combination of factors related to Mirum Pharmaceuticals’ strategic acquisition and promising market potential. The acquisition of Bluejay Tx is seen as a highly favorable move, with the potential for significant clinical and regulatory success. The deal is structured with a strong probability of success, and the expected commercial synergies suggest that Mirum Pharmaceuticals would only need to achieve a modest level of peak sales to break even.
Moreover, the clinical data supporting the acquisition is robust, with a logical mechanism of action and strong Phase 2 results. The upcoming Phase 3 studies are anticipated to have a high probability of success, particularly in comparison to existing treatments. The market size for the HDV indication is substantial, with Mirum Pharmaceuticals projecting significant peak sales both in the U.S. and internationally. These factors contribute to a positive outlook for the company’s stock, justifying the Buy rating and the updated price target of $94 per share.
According to TipRanks, Clark-Gartner is a 5-star analyst with an average return of 27.4% and a 68.57% success rate. Clark-Gartner covers the Healthcare sector, focusing on stocks such as AbbVie, Vera Therapeutics, and Insmed.
In another report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $130.00 price target.